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Abstract
Although behavioral weight loss interventions generally have been shown to improve depressive 
symptoms, little is known as to whether some people with major depressive disorder experience 
worsening of depression during a weight loss intervention. We examined rates and predictors of 
change in depression symptoms among 148 obese women with major depressive disorder who 
participated in a trial comparing depression treatment plus behavioral weight loss treatment 
(Behavioral Activation; BA) to behavioral weight loss treatment alone (Lifestyle Intervention; LI). 
A statistically reliable change in depression was calculated as ≥ 9 points on the Beck Depression 
Inventory in this sample. At 6 months, 73% of participants in BA and 54% of participants in LI 
showed reliable improvement in depression symptoms and 1.5% of participants in BA and 1.3% 
of participants in LI showed reliable worsening in depression symptoms. Rates of reliable change 
were similar at 12 months. Participants who experienced reliable improvement in depression lost 
significantly more weight than those who did not in both conditions. In the LI condition, baseline 
psychiatric variables and change in physical activity during treatment were also related to reliable 
improvement in depression. We found no evidence for an iatrogenic effect of behavioral weight 
loss treatment on depressive symptoms among obese women with major depressive disorder; 
rather, behavioral weight loss treatment appears to be associated with significant concurrent 
improvement in depression. Even greater rates of reliable improvement were observed when 
depression treatment was added to weight loss treatment.
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Introduction
Depression is commonly encountered in clinically obese patients (1, 2). Behavioral weight 
loss interventions result in improved depressive symptoms in samples not selected for 
depression (3). However, examining average pre to post-treatment changes in depression 
during treatment may mask patients experiencing an iatrogenic (i.e., worsening depression) 
response to weight loss treatment. Three recent studies have examined individual trajectories 
of depression change during behavioral weight loss treatment.
Faulconbridge and colleagues (2009)(4) examined depression symptom change in non-
depressed participants who received one of four weight loss treatments (sibutramine alone, a 
behavioral weight loss treatment alone, sibutramine + a behavioral weight loss treatment, 
and sibutramine + brief lifestyle visits with a primary care provider). They found that 8.5% 
of patients in the behavioral weight loss treatment alone condition experienced a 5-point or 
greater increase on the Beck Depression Inventory-II (BDI(5)) over 12 months of treatment. 
During the same time frame, 34.0% of the patients in the behavioral weight loss treatment 
alone condition experienced a 5 BDI point or greater decrease in depression symptoms. 
Across all four conditions, they found that a psychiatric history predicted 5-point or greater 
increases in BDI and that those with increased depression symptoms during treatment also 
lost less weight. However, it is possible that these relationships were primarily driven by the 
three of four treatment conditions that included sibutramine (i.e., it is unclear if these 
relationships were similar specifically in the behavioral weight loss treatment alone 
condition).
Faulconbridge and colleagues (2012)(6) continued this line of work with a secondary 
analysis of the Look AHEAD study, which tested the efficacy of a behavioral weight loss 
treatment in a primarily non-depressed sample (82.8% had BDI < 10 at baseline) of 
overweight and obese participants with type 2 diabetes. The Look AHEAD randomized trial 
compared behavioral weight loss treatment to a minimal education and support control 
group. Among those that received the behavioral weight loss intervention, they found that 1) 
6.3% patients who were non-depressed at baseline (i.e., BDI <10) had clinically significant 
depression symptoms (i.e., BDI ≥ 10) at 1 year follow-up and 2) 60.8% of those with 
clinically significant depression symptoms at baseline were non-depressed at 1 year follow-
up. Change in depression status between baseline and follow-up was significantly associated 
with concurrent change in weight, such that development of clinically significant depression 
symptoms was associated with less weight loss and resolution of clinically significant 
depression symptoms was associated with greater weight loss.
In a sample of obese women with moderate or greater depression symptoms, Simon and 
colleagues (7) examined changes in depression in participants randomized to either a 
behavioral weight loss intervention or a behavioral weight loss intervention integrated with 
CBT for depression. They found that 10% of participants experienced increases in 
depression symptoms and 33% experienced decreases in depression symptoms during 
treatment, but they did not examine differences between treatment conditions. Similar to the 
two studies reviewed above, they found that change in depression symptoms during 
treatment (i.e. increasing vs. stable vs. decreasing) was positively associated with concurrent 
Busch et al. Page 2
Obesity (Silver Spring). Author manuscript; available in PMC 2013 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
changes in weight such that those with decreases in depression lost the most weight, while 
those with increases in depression lost the least weight. In addition, they found that those 
with decreases in depression had the largest increases in physical activity, while those with 
increases in depression had the smallest increases in physical activity. Change in depression 
symptoms was not associated with change in energy intake
None of the above studies used an established method for setting a cut-off for meaningful 
change in depression symptoms. Although Faulconbridge and colleagues (2012)(6) used a 
well established cutoff for clinically significant symptoms on the BDI (i.e., BDI ≥ 10), a 
patient with very little change in BDI score over 1 year could be classified as developing 
clinically significant depression symptoms (e.g., a patient with a BDI of 8 at baseline and 10 
at 1 year follow-up was classified as developing clinically significant depression symptoms 
when their BDI score only changed by two points).
Thus it is unclear whether the degree of change reported in these studies is within the range 
that would be expected simply due to the less than perfect reliability of instrument used to 
measure depression. Extensive previous work has developed equations for calculating 
statistically reliable change that take into account the reliability of the instrument used to 
measure depression (the “Reliable Change Index” (8, 9).
Data from the Be Active trial (10, 11) provides an opportunity to examine the rates of 
statistically reliable improvement and worsening of depression symptoms among obese 
women with major depressive disorder (MDD) during either a behavioral weight loss 
intervention alone or one integrated with depression treatment. Secondarily, we explored 
baseline predictors of reliable changes in depression, with a particular focus on psychiatric 
factors (e.g., anti-depressant status, co-morbid psychiatric diagnoses) in order to follow-up 
on previous findings (4). Finally, we explored the association between reliable depression 
change and concurrent changes in energy intake, physical activity, and weight. We 
conducted analyses within each condition in order to present the first data on predictors of 
individual changes in depression during a behavioral weight loss treatment alone (i.e., not 
combined with other treatment). We also extend upon previous work by controlling for 
baseline depression in regression analyses.
Method and Procedures
Participants were enrolled in a randomized clinical trial testing whether adding behavioral 
treatment for depression to a behavioral weight loss intervention improves weight loss 
relative to a behavioral weight loss intervention alone in women with co-morbid obesity and 
depression (10). The design and methods of this trial have been described in detail elsewhere 
(11). All procedures were approved by the Internal Review Board of the University of 
Massachusetts Medical School.
Participants were women between the ages of 21 and 65 years who met criteria for MDD via 
a structured clinical interview (12), but were not actively suicidal, had not been hospitalized 
for psychiatric issues in the previous 12 months, and were not currently in psychotherapy. 
Other exclusion criteria included: smoking; bipolar disorder, psychotic disorder, bulimia, or 
post-traumatic stress disorder; diabetes; bariatric surgery; inability to walk unaided for 0.25 
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miles or lack of clearance from a primary care provider for physical activity; conditions 
prohibiting dietary changes; medical conditions likely to limit lifespan; current weight loss 
treatment; taking medications known to affect appetite and/or weight; pregnant or trying to 
become pregnant; and non-English speaking. Participants on antidepressant medication 
needed to have a period of no dose change of 3 months before enrolling in the intervention.
Treatment Conditions
Participants were randomized to one of two conditions; Behavioral Activation (BA; 
depression treatment followed by a lifestyle intervention) or a Lifestyle Intervention with 
attention control visits (LI). BA and LI conditions included a 6-month (weeks 1–24) 
Intensive Treatment phase (ten-60 minute individual sessions and sixteen 90-minute group 
sessions) and a 6 month Maintenance Phase (6 monthly 90-minute group sessions and 6 
monthly 20-minute counseling phone calls). In both conditions, group sessions during the 
Intensive Treatment and Maintenance Phases followed the Diabetes Prevention Program 
(DPP(13)) Lifestyle Intervention protocol. All groups were led by either a dietitian or an 
exercise physiologist. The content of these groups was identical across conditions. The 
timing of group visits and the content of the individual intensive phase sessions and 
maintenance phase phone calls distinguished conditions.
BA Condition—In the BA condition, the 10 individual sessions during the intensive 
treatment phase were focused on behavioral depression treatment (see below) and were 
conducted by master’s- and doctoral-level counselors under the supervision of a licensed 
clinical psychologist. These individual sessions occurred weekly during the first 10 weeks of 
treatment (weeks 1–10). The group behavioral weight loss sessions during the intensive 
treatment phase started at week 9 and continued to the end of the intensive phase (weeks 9–
24). During the maintenance phase for BA participants, the monthly 20-minute counseling 
phone calls also focused on depression treatment.
The depression treatment was based on the brief behavioral activation treatment developed 
by Lejuez and colleagues (14). Meta-analytic findings support the efficacy of this approach 
(15). Behavioral activation is posited to improve depression by increasing the patient’s 
contact with positive reinforcement through collaborative, structured activity scheduling. 
These out-of-session activity assignments are explicitly focused on the patient’s life values, 
and much of counseling sessions focus on problem-solving assignment completion. BA 
sessions were exclusively focused on depression treatment. Thus, BA therapists did not 
monitor or provide recommendations for diet or physical activity changes.
LI Condition—In the LI condition, both the 16 group weight loss sessions and the 10 
individual sessions started at week 1 and were spread throughout the intensive phase (weeks 
1–24). Both the intensive phase individual counseling sessions and the monthly maintenance 
phase phone calls focused on general health education (i.e., attention control). The content 
of health education sessions and calls were determined by the participant who could select 
from 23 health topics relevant to women’s health (e.g., skin health, proper footwear). These 
contacts were conducted by health educators with no training in psychological or lifestyle 
counseling.
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Main Trial Results
In the main analyses of this trial, there were no differences between the BA and LI 
conditions in weight loss (10), however participants in the BA condition experienced better 
depression outcomes (16), including higher rates of response and remission on the BDI. 
Pagoto and colleagues (10) also reported that participants who experienced depression 
response or remission also experienced greater concurrent weight loss.
Measures
Depression, weight, energy intake, and physical activity were assessed at baseline, 6 months, 
and 12 months. We report on changes in these variables between baseline and the follow-up 
time points. Throughout the results, negative change scores indicate decreasing values and 
positive change scores indicate increasing values.
Depression—MDD diagnosis was determined before enrollment though the Structured 
Clinical Interview for DSM-IV (12) with a trained assessor. Severity of depression 
symptoms was measured using the Beck Depression Inventory-II (BDI; (5)), a 21-item self-
report scale that assesses mood over the previous 2 weeks. Possible BDI scores range from 
0–63 with higher scores indicating greater depressed mood. The reliability and validity of 
the BDI is well established (17) and the reliable change index has been calculated on the 
BDI in several past depression treatment studies (18–22).
Reliable change is calculated using a scale’s internal consistency and standard deviation 
within the sample for which it is to be applied (8). The cut-off for reliable change is 
calculated as 1.96 times the standard error of the difference between scores of a given 
measure administered on two occasions (SEDiff;). RCI cut off was calculated using the 
following formula:
SDpre represents total score standard deviation at baseline and α represents scale reliability. 
This sample was large enough that standard deviation and reliability at baseline provide 
reasonable estimates of these statistics among women with co-morbid obesity and 
depression. Thus, baseline BDI data, rather than general population psychometric data, were 
used to calculate a reliable change cut-off. Only participants with a baseline BDI and either 
a 6-month or 12-month BDI (n = 148) were included in this calculation (as only these 
participants were included in later depression change analyses). The standard deviation of 
the BDI at baseline (SDPre) was 5.74 and Cronbach’s alpha (α) was .73. A SEDiff of 4.22 
and a reliable change cut-off of 8.27 were computed for the current sample. Thus, any 
change of ≥ 9 BDI points was considered a reliable change in the forthcoming analyses. Of 
note, our sample calculated reliable change cut-off ≥ 9 BDI points is the same as what has 
been suggested as by experts as a cut-off for statistically reliable change on the BDI in non-
obese samples (23). We categorized participants as experiencing a reliable worsening of 
depression (≥ 9 BDI point increase), no reliable change (less than 9 point change in either 
direction), and reliable improvement in depression (≥ 9 BDI point decrease).
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Weight—Weight was measured using a digital Tronix scale in light clothing and without 
shoes. Weight is reported in pounds (lbs).
Energy Intake—Average daily energy intake (kcal) was calculated at each time point 
using 24-hour diet recalls on 3 randomly-selected days (2 weekdays, 1 weekend day) within 
a 3-week window. Interviews were computer-guided and utilized a multiple-pass diet recall 
technique. Interviews were conducted by registered dietitians who were blind to treatment 
condition. The data produced by these interviews was analyzed using Nutrition Data System 
for Research (NDSR; version 2010, Nutrition Coordinating Center, University of Minnesota, 
MN;(24, 25)) to produce an average calories per day value (kcal).
Physical Activity—Average daily energy expended in sport and leisure physical activity 
(METs) was also assessed during the 24-hour recall phone calls described above. Daily 
METs were calculated based on participant report of time engaged in mild, moderate, hard, 
and very hard physical activity across multiple sport and leisure activities.
Other Psychiatric Variables
Five psychiatric variables were assessed at baseline. Participants self-reported current anti-
depressant medication status (yes/no). Past MDD diagnosis (yes/no) and other axis-I 
psychiatric diagnoses (yes/no) were assessed using the Structured Clinical Interview for 
DSM disorders (12). Possible co-morbid diagnoses were: substance (including alcohol) 
abuse or dependence, panic disorder, social phobia, specific phobia, obsessive compulsive 
disorder, and generalized anxiety disorder. Note that some co-morbid psychiatric diagnoses 
(e.g., bipolar disorder) were exclusion criteria.
Attention deficit/hyperactivity disorder (ADHD) symptomatology was measured using the 
Adult ADHD Self-Report Scale (ASRS;(26)). While the total ASRS has 18 items, 6 items 
(ASRS part A) have been found to be most predictive of ADHD and are used as a 
dichotomous screener. Specifically, those likely to have ADHD (≥4 of 6 symptoms) are 
distinguished from those unlikely to have significant ADHD symptoms (<4 of 6 symptoms). 
An ADHD screener was included in the original trial and the current analysis due to recent 
research suggesting that ADHD is highly co-morbid with obesity and predicts poor 
outcomes in behavioral weight loss treatment (27–29).Hedonic capacity (i.e., potential to 
experience positive affect) was measured using the 36-item self-reported Fawcett-Clark 
Pleasure Capacity Scale (FCPS;(30)). Items ask about the degree of pleasure that would be 
experienced in several hypothetical pleasurable situations across several domains. 
Reliability and validity have been established in clinical and non-clinical samples (31). 
Hedonic capacity was measured in this trial because, its inverse anhedonia, is a hallmark 
symptom of depression and is important to BA’s purported mechanism of change. High 
scores on the FCPS indicate higher levels of hedonic capacity.
Analytic Plan
Of the 161 women enrolled in the Be Active trial, we excluded from our analyses women 
missing BDI scores at both 6 and 12 months (because no reliable change could be 
calculated). Rates of reliable depression change are presented for baseline to 6-month 
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follow-up and baseline to 12-month follow-up. Because we were specifically interested in 
predictors of depression change category within each treatment group, we followed the 
recommendation of Rosenthal and colleagues (32) for “focused” analyses. Accordingly, we 
tested our hypotheses regarding prediction of depression change category through 
orthogonal a priori contrasts within both treatment groups.
We present bivariate (i.e., t-tests, Mann-Whitney U Tests, and χ2 tests) and multivariate 
relationships between depression change category at 6 months and 1) baseline 
characteristics, and 2) change in weight, energy intake, and physical activity between 
baseline and 6 months. We chose 6 months because it marked the end of intensive treatment. 
For multivariate analyses, three separate, three-step hierarchical logistic regressions were 
run for each of the two treatment conditions (i.e., BA and LI) to test if baseline to 6-month 
changes in weight, energy intake, or physical activity were related to 6-month reliable 
change in depression after controlling for baseline variables. Baseline depression was 
entered in Step 1 for all models to control for any variance caused by floor (i.e., participants 
with lower baseline BDI scores may be less likely to fall by 9 points) or regression to the 
mean effects. Other baseline predictors included in Step 2 of all models were to control for 
potential confounders and were informed by bivariate relationships between baseline 
variables and depression change category. Specifically, baseline variables with a p < .10 
bivariate relationship with reliable change in either condition were entered into Step 2. Step 
3 added change in weight, energy intake, or physical activity during treatment as predictors, 
entered in separate models. Finally, in order to facilitate direct comparison with previous 
work with non-depressed samples using the BDI(4), we calculated the proportion of 
participants with a change of five or more BDI points in either direction between baseline 
and 12 month follow up.
Results
All participants in the Be Active trial (10, 11) with BDI scores at baseline and either 6-
months or 12 months were included in the current study (n = 148, 91.9% of randomized 
sample). Participants were primarily married or living with a partner (67.6%), Caucasian 
(85.8%), employed full time (65.5%) and had some post-high school education (some 
college or trade school; 91.9%). Mean age was 46.0 years (SD = 10.95) and median 
household income was $50,000–60,000 per year. Baseline BDI in this sample ranged from 
12 to 38 with a mean of 21.0. There were no significant differences between treatment 
conditions on any of these variables.
Figure 1a presents the rates of participants with reliable worsening in depression (1.5% in 
BA, 1.3% in LI), reliable improvement in depression (73.1% in BA, 53.9% in LI), and no 
reliable change in depression (25.4% in BA, and 44.8% in LI) between baseline and 6 month 
assessment. Figure 1b presents these categories between baseline and the 12 month 
assessment (reliable worsening: 1.5% in BA, 1.4% in LI; reliable improvement: 69.2% in 
BA, 55.7% in LI; no reliable change: 29.3% in BA, 42.9% in LI). The rate of reliable 
improvement was significantly higher in BA relative to LI between baseline and 6 months 
(χ2 = 5.62, p =.02), but no significant difference was observed between conditions on 
reliable improvement from baseline and 12 months (χ2 = 2.62; p = .11). Of those who had 
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experienced a reliable improvement by 6 months, 86.4% in the BA condition and 76.3% in 
the LI condition maintained that improvement at 12 months.
Because of the low rate of participants experiencing reliable worsening in depression 
(<1.5% of the total sample) both those with no reliable change in depression and those who 
experienced reliable worsening were collapsed into one category. For clarity, this combined 
group will be referred to as non-responders. Further analyses compared those experiencing 
non-response to those experiencing reliable improvement.
Table 1 presents the bivariate relationships between baseline and treatment variables and 
depression change category at 6 months. Among women in the BA condition greater weight 
loss during treatment was significantly associated with reliable improvement (t(65) = 2.47, p 
= .02) and, greater baseline physical activity was marginally associated with reliable 
improvement (METs; Z =1.93, p = .053)1. Among women in the LI condition, higher 
baseline depressive symptoms (BDI; t(72) = 3.33, p = .001), absence of baseline ADHD 
symptoms (χ2 = 4.82, p =.03), lower hedonic capacity (t(72) = 2.24, p = .03), and greater 
weight loss during treatment (t(73) = 3.66, p < .001) were significantly associated with 
reliable improvement in depression. Absence of co-morbid psychiatric diagnoses at baseline 
(χ2 = 3.12, p =.08) and greater reduction in energy intake (t(72) = 1.78, p = .08) were also 
marginally related to reliable improvement in the LI condition.
Logistic regression models can be seen in Table 2. Based on bi-variate relationships, 
baseline physical activity (METs), ADHD symptoms, co-morbid psychiatric diagnosis, and 
hedonic capacity were included as predictors in Step 2. The level of multicollinearity among 
these baseline predictor variables did not preclude them from being entered into the same 
model (all rs < .35). In the BA condition, no step 1 or step 2 predictors were significant, but 
greater baseline physical activity was marginally related to reliable improvement (p = .06). 
In step 3 models in the BA condition, only change in weight was a marginally significant 
predictor (p = .07). In the LI condition, higher baseline depression significantly predicted 
reliable response in Step 1 (p < .01). In Step 2, the absence of ADHD symptoms 
significantly (p = .04) and the absence of other psychiatric diagnoses marginally (p = .07) 
predicted reliable response. Greater reduction in weight (p = .001) and greater increase in 
physical activity (p = .01) were each significant predictors of reliable response in step 3 
models in the LI condition.
For comparison to Faulconbridge and colleagues’ (2009) (4) non-depressed sample, we 
performed similar analyses using the cut-off they used. Recall that Faulconbridge and 
colleagues found that among their patients in the behavioral weight loss treatment alone 
condition, 34% experienced ≥5 BDI point reduction at 1 year, while 8.5% experienced a ≥5 
BDI point increase at 1 year. In the LI condition of the current study 77.1% of participants 
experienced ≥5 BDI point reduction in depression and 4.29% experienced a ≥5 BDI point 
increase in depression between baseline and 1 year. In the BA condition, 81.5% of 
1Baseline physical activity data was significantly positively skewed. Thus, the non-parametric Mann-Whitney U Test was used, rather 
than a t-test. Median and IQR are reported in Table 1 rather than mean and SD.
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participants experienced ≥5 BDI point reduction in depression and 6.15% experienced a ≥5 
BDI point increase in depression between baseline and 1 year.
Discussion
Results indicate that very few participants (<2%) experienced a reliable increase in 
depression symptoms during treatment. In fact, the majority of participants (63% of the total 
sample) experienced reliable improvement in depression (≥9 BDI point decrease) during 
treatment, even in the LI condition (54%) where depression was not specifically treated. 
These findings raise the possibility that behavioral weight loss treatment alone has 
significant antidepressant effects.
We also used a 5 BDI point or greater cut-off to allow for a direct comparison with 
Faulconbridge and colleagues (2009) (4). We found that participants in the LI condition 
were more likely to experience 5 BDI point improvements in depression at 1 year follow up 
(77.1%) than the non-depressed participants in Faulconbridge and colleagues in a similar 
behavioral weight loss treatment condition (34.0%). Further, worsening of depression by 
five or more BDI points was half as likely in our LI condition (4.29%) as in the 
Faulconbridge and colleagues behavioral weight loss treatment condition (8.5%). It is 
possible that these differences between Faulconbridge and colleagues’ non-depressed 
sample and the current study’s depressed sample were caused by regression to the mean or 
spontaneous recovery due to the natural episodic course of depression in the current study. 
Nonetheless, it appears that those with MDD are more likely to experience improvement and 
less likely to experience worsening of depression during a behavioral weight loss treatment 
than non-depressed patients.
Across both cut-off thresholds, results suggest that behavioral weight loss treatment does not 
exacerbate depression symptoms and is therefore not contraindicated in depressed patients. 
However, several studies have shown that those with depression lose less weight in 
behavioral weight loss treatments (e.g., (1, 33, 34)), and that improvement in depressive 
symptoms during behavioral weight loss treatment is associated with concurrent weight loss 
(4, 6, 7, 35). Therefore, depression still appears to pose a barrier to weight loss even though 
symptoms tend to improve during behavioral weight loss treatment. The parent study also 
revealed that depression response and remission were associated with greater weight losses 
(10).
In the LI condition, higher depression symptoms, lower hedonic capacity, and the absence of 
ADHD symptoms were significantly associated with greater likelihood of experiencing a 
reliable improvement in depression. The absence of a co-morbid psychiatric condition was 
also marginally (p<.10) predictive of experiencing reliable improvement in depression. The 
strong relationship between baseline depression and depression change category in the LI 
condition likely represents a combination of regression to the mean and floor effects (i.e., 
one is more likely to improve by ≥ 9 BDI points if starting from a BDI of 30 than from a 
BDI of 13). Further, the counterintuitive finding regarding hedonic capacity is likely an 
artifact of these effects, as anhedonia is a symptom of depression. This interpretation is 
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supported by the finding that hedonic capacity was not predictive of reliable improvement 
after controlling for baseline depression in multivariate analyses (Step 2, Table 2).
Findings in the LI condition showing that co-morbid psychiatric diagnosis and ADHD 
symptoms were associated with non-response are consistent with the Faulconbridge and 
colleagues (2009) (4) finding that general psychiatric history at baseline predicted 
depression worsening during treatment. It is notable that a positive screen for ADHD 
symptoms at baseline was significantly associated with a lower likelihood of experiencing 
reliable improvement in depression in both bi-variate and multivariate analyses (Step 2, 
Table 2) because of the recently established link between obesity and ADHD (27–29).
In the BA condition, greater baseline leisure time physical activity was marginally related to 
reliable improvement in both bivariate and multivariate comparisons. It is possible that the 
focus of BA on activation was particularly helpful among those who were more physically 
active. The absence of psychiatric variables predicting depression change category in the BA 
condition in either bi-variate or multivariate analyses suggests that Behavioral Activation 
may buffer some of the negative effects emanating from pre-existing psychiatric diagnoses, 
although the processes by which this might happen are unclear.
Our observation that reliable improvement in depression in both conditions is related to 
greater concurrent weight loss replicates the findings of previous studies (4, 6, 7), but in a 
sample that was selected for MDD per a diagnostic interview. Unlike previous studies, we 
demonstrated this relationship in the LI condition after controlling for multiple baseline 
variables associated with depression change. Most importantly, the current study controlled 
for baseline depression (thus controlling for floor and regression to the mean effects) and 
psychiatric factors that predict depression change. However, because depression change and 
weight change were measured concurrently, no direct causal conclusions can be made from 
this data.
Consistent with Simon and colleagues (7), we found no significant relationships between 
depression change status and change in energy intake. In bivariate analyses we were unable 
to replicate Simon and colleagues finding that changes in physical activity are related to 
changes in depression symptoms. However, in the LI condition after controlling for baseline 
variables, greater increases in physical activity were significantly associated with higher 
rates of reliable improvement in depression. This finding is consistent with data supporting 
exercise as a promising treatment for depression (e.g., (36)). However, no causal 
conclusions can be drawn regarding physical activity change and depression change status 
due to concurrent measurement.
This study is the first to examine individual participant changes in depression during 
behavioral weight loss treatment among those with diagnosed MDD by structured interview. 
Strengths include the use of an established method of determining a cut-off for significant 
change in depression (“Reliable Change Index”; (8)) and control for baseline confounders. 
However, some study limitations are notable. First, this sample was restricted to women 
aged 21–65 years, so it is unknown if these findings generalize to men or women of other 
age groups. It is notable that the Simon and colleagues study (7) also only included women 
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and the Faulconbridge and colleagues (2009) study (4) sample was about 80% women, 
while studies suggesting that weight loss can trigger significant increases in depression (37) 
included only men. Second, this study excluded the most severely depressed patients, thus 
this study does not speak to possible iatrogenic effects in patients with the most severe 
depression. Finally, the results described here should not be interpreted regarding the 
comparative efficacy of BA vs. LI on depression symptoms. The current analyses were 
specifically designed to explore the rate and predictors of significant changes in depression 
within each treatment. The main outcome paper for the Be-Active trial (10) should be the 
primary resource for questions regarding treatment efficacy.
Although this study and others have shed some light on the rates of depression change 
during behavioral weight loss treatment, the exact processes through which depression 
change occurs (improvement or worsening) are not well understood. For example the 
temporal relationship between changes in depression and changes in weight during treatment 
is unknown. Further, plausible physiological and psychological mediators of the relationship 
between weight and depression during weight loss treatment remain unexplored. For 
example, it is possible that the social reinforcement one receives for losing weight or body 
image changes following weight loss drive depression changes. It is also possible that 
behavioral weight loss treatment itself (e.g., social support, working toward weight loss 
goals, etc) is activating enough to have a significant effect on depression among those with 
MDD. These possibilities should be explored in future studies.
In summary, we found that the majority of women in our sample experienced reliable 
improvement in depression during the trial, regardless of whether they received depression 
treatment in addition to behavioral weight loss treatment. Less than 2% of all participants 
experienced a reliable worsening of depression. Our results suggest that behavioral weight 
loss treatments are unlikely to cause significant worsening of depression in obese women 
with MDD and may cause significant improvements. We also replicated previous findings 
indicating that improvement in depression during weight loss treatment is associated with 
better weight outcomes. The existence of a concurrent relationship between weight 
reduction and depression improvement during weight loss treatment is now well established 
and future research aimed at explaining this relationship is warranted.
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Figure 1. 
Rates of reliable changes in depression between baseline and 6 months (A) and between 
baseline and 12 months (B).
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